z-logo
open-access-imgOpen Access
Use of a Biventricular Assist Device in the Treatment of Acute Doxorubicin‐Induced Cardiotoxicity
Author(s) -
Swartz Michael F.,
Fink Gregory W.,
Carhart Robert L.
Publication year - 2004
Publication title -
congestive heart failure
Language(s) - English
Resource type - Journals
eISSN - 1751-7133
pISSN - 1527-5299
DOI - 10.1111/j.1527-5299.2004.02662.x
Subject(s) - medicine , cardiotoxicity , heart failure , inotrope , doxorubicin , ventricular assist device , cardiomyopathy , cardiology , ischemic cardiomyopathy , cardiac function curve , surgery , chemotherapy , ejection fraction
This report describes a patient treated for metastatic leiomyosarcoma, who acutely developed doxorubicin‐induced cardiotoxicity, and consequently developed heart failure. Medical therapy was initiated; however, her condition deteriorated and a surgical alternative was proposed. A biventricular assist device was implanted, allowing her multisystem organ failure to improve. During the next 9 days while on the assist device, her heart failure resolved, her organs were well perfused, and her heart entered a recovery period. After 9 days of mechanical support with the biventricular assist device, she was explanted from the assist device, and with inotropic support and an intra‐aortic balloon pump, she maintained adequate hemodynamics. Eighteen days after implantation of the assist device, she was discharged from the hospital with hospice care, where she later died. Although the patient's cardiac function did not have long‐term recovery, short‐term recovery after doxorubicin toxicity was achieved. The authors maintain that the use of a biventricular assist device in the treatment of acute heart failure resulting from doxorubicin‐induced cardiomyopathy is an effective way to manage this patient population.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here